Literature DB >> 6811517

HLA-DR-associated genetic control of the type of leprosy in a population from surinam.

W van Eden, R R de Vries, J D'Amaro, I Schreuder, D L Leiker, J J van Rood.   

Abstract

The relationship between HLA phenotype and leprosy classification was studied in 73 unrelated patients and 92 healthy controls from a mixed Negroid-Caucasoid population originating from Surinam, South America. Heterogeneity in the distribution of HLA-DR (but not A, B, and C) was detected between tuberculoid (TT* + BT*) leprosy and lepromatous (BL* + LL*) leprosy patients (p = 0.024). This heterogeneity appeared to be caused almost exclusively by DR3. Most significantly, the frequency of DR3 was increased among polar tuberculoid (TT) leprosy patients as compared to the rest of the patients (p = 0.0003). Compared with healthy controls the frequency of DR3 was increased among TT patients (p = 0.006), unchanged in BT patients, and decreased among lepromatous (BL + LL) patients (p = 0.027). These data indicate that in this population an DR3-associated factor controls the type of the disease that develops after infection with Mycobacterium leprae.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6811517     DOI: 10.1016/0198-8859(82)90007-6

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  13 in total

1.  HLA-DR and tuberculin tests in rheumatoid arthritis and tuberculosis.

Authors:  G M Bahr; M A Sattar; J L Stanford; M A Shaaban; B Al Shimali; Z Siddiqui; M Gabriel; M Al Saffar; A Shahin; T D Chugh
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

2.  Low T lymphocyte responsiveness to Mycobacterium leprae antigens in association with HLA-DR3.

Authors:  W van Eden; B G Elferink; R R de Vries; D L Leiker; J J van Rood
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

3.  Analysis of human antibody epitopes on the 65-kilodalton protein of Mycobacterium leprae by using synthetic peptides.

Authors:  H C Meeker; D L Williams; D C Anderson; T P Gillis; G Schuller-Levis; W R Levis
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

4.  T-cell recognition of mycobacterial GroES peptides in Thai leprosy patients and contacts.

Authors:  B Chua-Intra; S Peerapakorn; N Davey; S Jurcevic; M Busson; H M Vordermeier; C Pirayavaraporn; J Ivanyi
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

5.  Use of recombinant antigens expressed in Escherichia coli K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of Mycobacterium bovis BCG.

Authors:  J E Thole; W C van Schooten; W J Keulen; P W Hermans; A A Janson; R R de Vries; A H Kolk; J D van Embden
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

6.  HLA-DR3 associated genetic control of response to multiple skin tests with new tuberculins.

Authors:  W van Eden; R R de Vries; J L Stanford; G A Rook
Journal:  Clin Exp Immunol       Date:  1983-05       Impact factor: 4.330

7.  I-A restricted activation by T cell lines of anti-tuberculosis activity in murine macrophages.

Authors:  G A Rook; B R Champion; J Steele; A M Varey; J L Stanford
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

Review 8.  Infectious diseases and immunity: special reference to major histocompatibility complex.

Authors:  N Singh; S Agrawal; A K Rastogi
Journal:  Emerg Infect Dis       Date:  1997 Jan-Mar       Impact factor: 6.883

9.  Evidence for an association of HLA-DRB1*15 and DRB1*09 with leprosy and the impact of DRB1*09 on disease onset in a Chinese Han population.

Authors:  Furen Zhang; Hong Liu; Shumin Chen; Changyuan Wang; Chuanfu Zhu; Lin Zhang; Tongsheng Chu; Dianchang Liu; Xiaoxiao Yan; Jianjun Liu
Journal:  BMC Med Genet       Date:  2009-12-11       Impact factor: 2.103

10.  Arginine at positions 13 or 70-71 in pocket 4 of HLA-DRB1 alleles is associated with susceptibility to tuberculoid leprosy.

Authors:  L Zerva; B Cizman; N K Mehra; S K Alahari; R Murali; C M Zmijewski; M Kamoun; D S Monos
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.